Similar articles

• Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.

  Hiransuthikul N, Hiransuthikul P, Kanasook Y. Hiransuthikul N, et al. Southeast Asian J Trop Med Public Health. 2007 Jan;38(1):69-77. Southeast Asian J Trop Med Public Health. 2007. PMID: 17539249
• Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

  Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ. Nguyen ST, et al. Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323. Pharmacotherapy. 2008. PMID: 18294112
• Hepatitis C management in HIV infection--where is the controversy?

  Dieterich DT. Dieterich DT. AIDS Read. 2002 Jan;12(1):22-3. AIDS Read. 2002. PMID: 11862657 No abstract available.
• HIV and hepatitis C coinfection.

  Matthews GV, Dore GJ. Matthews GV, et al. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1000-8. doi: 10.1111/j.1440-1746.2008.05489.x. J Gastroenterol Hepatol. 2008. PMID: 18707597 Review.
• Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.

  Vogel M, Rockstroh JK. Vogel M, et al. Curr Opin HIV AIDS. 2009 May;4(3):171-5. doi: 10.1097/COH.0b013e328329c602. Curr Opin HIV AIDS. 2009. PMID: 19532046 Review.